Search This Blog

Wednesday, May 7, 2025

NIH, CMS tie up for autism research with Medicare and Medicaid data

 The National Institutes of Health and the Centers for Medicare & Medicaid Services have partnered to enable research around the root causes of the autism spectrum disorder by creating a database of Medicare and Medicaid enrollees with a diagnosis of the condition, the agencies said on Wednesday.

The partnership will help NIH to build a real-world data platform enabling advanced research across claims data, electronic medical records, and consumer wearables.

It will first focus on research around the root causes of autism, and in the long term link real-world data for research on chronic conditions.

"We're pulling back the curtain — with full transparency and accountability — to deliver the honest answers families have waited far too long to hear," said U.S. Department of Health and Human Services Secretary Robert F. Kennedy, Jr.

Researchers will focus on autism diagnosis over time, health outcomes from medical and behavioral interventions, access to care and disparities by demographics and geography as well as the economic burden on families and healthcare systems.

Autism is a neurological and developmental condition marked by disruptions in brain-signaling that cause people to behave, communicate, interact, and learn in atypical ways.

Earlier in April, the U.S. health secretary said environmental contributors to autism are behind its rising prevalence, adding he plans to look at everything from mold to medicine to identify them.

Rates of autism spectrum disorder among U.S. children reached a record level in 2022, continuing a recent trend of increasing prevalence.

There are no treatments or cures for autism, nor can it be reversed. However, experts agree that early diagnosis is crucial. Intervention with supportive measures – ideally before age three - is critical for improving cognitive, social and communication skills.

https://gazette.com/news/us-world/nih-cms-tie-up-for-autism-research-with-medicare-and-medicaid-data/article_65e9f932-438b-5b9c-8ba6-ead2cd4a8865.html

Myriad Genetics Reports 3% Decline in Q1 2025 Revenue; Updates Financial Guidance

 Myriad Genetics reports Q1 2025 revenue of $196 million, down 3% YoY, with varied performance across product lines.

Updated 2025 financial guidance with revenue in a range of $807 - $823 million and adjusted EPS range of $(0.02) - $0.02, reflecting first quarter 2025 results and the current business outlook.

Myriad Genetics, Inc. reported a 3% decline in first-quarter 2025 revenue, totaling $196 million, although revenue increased by 5% when excluding certain headwinds. Prenatal testing revenue grew by 11% year-over-year, while Pharmacogenomics revenue fell by 20% due to reduced coverage for GeneSight by UnitedHealthcare. The company's gross margin rose to 69%, benefiting from improved lab efficiencies. Myriad posted a GAAP net loss of $0.1 million, aided by a tax benefit of $29 million, while adjusted EPS was $(0.03). Following the quarter's results, the company adjusted its 2025 revenue guidance downward to a range of $807 - $823 million, reflecting challenges in its pharmacogenomics business and hereditary cancer testing. The leadership is focused on strategies to enhance execution and prioritize new product development despite current operational challenges.

https://www.nasdaq.com/articles/myriad-genetics-reports-3-decline-q1-2025-revenue-updates-financial-guidance-full-year

China urges state-backed tech players overseas to counter Trump tariffs

 Nikkei reports

https://www.marketscreener.com/quote/stock/LENOVO-GROUP-LIMITED-1412726/news/China-Urges-State-Backed-Tech-Players-Overseas-To-Counter-Trump-Tariffs-Nikkei-Reports-49847302/

Oscar Health beats Q1 2025 earnings expectations

 Oscar Health Inc. reported its first-quarter 2025 earnings, surpassing Wall Street expectations with an EPS of $0.92 against a forecasted $0.81. The company also exceeded revenue projections, reporting $3.05 billion compared to the anticipated $2.84 billion. Following the earnings announcement, Oscar Health’s stock surged 15.57% in premarket trading, reflecting investor optimism. With a market capitalization of $3.32 billion and impressive revenue growth of 56.54% over the last twelve months, Oscar Health continues to demonstrate strong momentum.

Key Takeaways

  • Oscar Health’s revenue grew by 42% year-over-year, reaching $3 billion.
  • The company reported a net income of $275 million, a $98 million improvement.
  • Earnings from operations increased by $112 million to $297 million.
  • The stock price rose significantly in premarket trading following the earnings beat.
  • Oscar Health’s membership grew by 41% year-over-year, ending the quarter with 2 million members.

Company Performance

Oscar Health demonstrated robust growth in Q1 2025, with significant year-over-year improvements in revenue and net income. The company’s strategic focus on technology and innovation has contributed to its rapid expansion in the individual insurance market. Oscar Health’s strong membership growth and improved operational efficiency underscore its competitive positioning amid market changes. 

Financial Highlights

  • Revenue: $3 billion, up 42% year-over-year
  • Earnings per share: $0.92, exceeding the forecast of $0.81
  • Net income: $275 million, a $98 million increase
  • Operating margin: 9.8%, a 110 basis point improvement
  • Medical Loss Ratio: 75.4%, a 120 basis point increase

  • Earnings vs. Forecast

Oscar Health’s Q1 2025 EPS of $0.92 surpassed the forecasted $0.81 by 13.6%. This earnings beat is a positive indicator compared to previous quarters and highlights the company’s strong financial management and operational efficiencies.

Market Reaction

Oscar Health’s stock experienced a notable increase of 15.57% in premarket trading, reaching $15.10. This surge reflects investor confidence in the company’s financial performance and growth prospects. 

Outlook & Guidance

Oscar Health projects total revenue for 2025 to be between $11.2 billion and $11.3 billion. The company anticipates an MLR of 80.7% to 81.7% and an SG&A expense ratio of 17.6% to 18.1%. Earnings from operations are expected to range from $225 million to $275 million. The company foresees continued membership growth in the first half of the year, with a potential decline in the latter half.

https://www.investing.com/news/transcripts/earnings-call-transcript-oscar-health-beats-q1-2025-earnings-expectations-93CH-4028505

LivaNova plc (LIVN) Tops Q1 EPS by 12c ; Guidance Tops Views

 LivaNova plc (NASDAQ: LIVN) reported Q1 EPS of $0.88, $0.12 better than the analyst estimate of $0.76. Revenue for the quarter came in at $316.9 million versus the consensus estimate of $302.38 million.

GUIDANCE:

LivaNova plc sees FY2025 EPS of $3.60-$3.70, versus the consensus of $3.58.

https://www.streetinsider.com/Earnings/LivaNova+plc+%28LIVN%29+Tops+Q1+EPS+by+12c+%3B+Offers+Guidance/24752918.html

BeiGene posts 46% 1st-qtr sales growth, bit misses consensus

 Sino American biotech BeiGene (Nasdaq: ONC; HKEX: 06160), a global oncology company that will change its name to BeOne Medicines, today announced financial results and corporate updates from the first quarter 2025.

Revenue for the first quarter of 2025 was $1.1 billion, up 46.3% compared to $752 million in the prior-year period driven primarily by growth in Brukinsa (zanubrutinib) product sales in the USA and Europe.

US sales of Brukinsa totaled $563 million, representing growth of 60% over the prior-year period driven primarily by demand, with more than 60% of the quarter-over-quarter growth coming from expanded use in chronic lymphocytic leukemia (CLL) as Brukinsa continued to gain share as the sales in Europe totaled $116 million in the first quarter, representing growth of 73% compared to the prior-year period, driven by increased market share across all major European markets, including Germany, Italy, Spain, France and the UK.

https://www.thepharmaletter.com/beigene-posts-46-percent-st-qtr-sales-growth-bit-misses-consensus

Potential U.S. Tariffs Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025



Alvotech (NASDAQ: ALVO), a global biotech company specializing in biosimilar medicines, has announced that potential U.S. tariffs on imported pharmaceuticals should have minimal impact on its 2025 product revenues. The company, which manufactures its biosimilars in Iceland, faces a minimum 10% tariff on U.S. imports. This tariff would increase costs for U.S. customers by less than 1% of Alvotech's expected 2025 product revenues.

According to contracted terms, customers are responsible for transport costs and import duties, not Alvotech. CEO Robert Wessman noted that Iceland's favorable trade balance with the U.S. makes higher tariffs unlikely, and emphasized that biosimilars remain the most cost-effective way to increase patient access to vital biologics. Beyond 2025, even with anticipated product launches and increased sales, the tariff impact would still represent a low single-digit percentage of total product revenues.